Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage

C. Caram-Deelder, H. McKinnon Edwards, JA. Zdanowicz, T. van den Akker, C. Birkegård, J. Blatný, JG. van der Bom, G. Colucci, D. van Duuren, N. van Geloven, DDCA. Henriquez, M. Knight, L. Korsholm, A. Landorph, G. Lavigne Lissalde, ZK. McQuilten,...

. 2024 ; 13 (9) : . [pub] 20240501

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24012872

Grantová podpora
Sponsor Novo Nordisk (Denmark)

Background: Despite a range of available treatments, it is still sometimes challenging to treat patients with severe post-partum hemorrhage (sPPH). Objective: This study evaluated the efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 (NCT04723979), OS-2, OS-3, and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligations, arterial embolization, or hysterectomy) and safety (incidence of thromboembolic events (TE) and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa-exposed women only. Results: A total of 446 women exposed to rFVIIa and 1717 non-exposed controls were included. In the RCT, fewer rFVIIa-exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio: 0.11; 95% confidence interval: 0.03-0.35). In OS-1, more rFVIIa-exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio: 2.46; 95% confidence interval: 1.06-5.99). In OS-2, 17% (3/18) of rFVIIa-exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio: 0.33; 95% confidence interval: 0.03-1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa-exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa on the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24012872
003      
CZ-PrNML
005      
20240726151433.0
007      
ta
008      
240723s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/jcm13092656 $2 doi
035    __
$a (PubMed)38731185
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Caram-Deelder, Camila $u Leiden University Medical Center, 2333 Leiden, The Netherlands $1 https://orcid.org/0000000331615684
245    10
$a Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage / $c C. Caram-Deelder, H. McKinnon Edwards, JA. Zdanowicz, T. van den Akker, C. Birkegård, J. Blatný, JG. van der Bom, G. Colucci, D. van Duuren, N. van Geloven, DDCA. Henriquez, M. Knight, L. Korsholm, A. Landorph, G. Lavigne Lissalde, ZK. McQuilten, D. Surbek, C. Wellard, EM. Wood, FJ. Mercier
520    9_
$a Background: Despite a range of available treatments, it is still sometimes challenging to treat patients with severe post-partum hemorrhage (sPPH). Objective: This study evaluated the efficacy and safety of recombinant activated factor VIIa (rFVIIa) in sPPH management. Methods: An open-label, multi-center, randomized controlled trial (RCT; NCT00370877) and four observational studies (OS; OS-1 (NCT04723979), OS-2, OS-3, and OS-4) were analyzed regarding efficacy (need for subsequent invasive procedures, including uterine compression sutures, uterine or iliac artery ligations, arterial embolization, or hysterectomy) and safety (incidence of thromboembolic events (TE) and maternal mortality) of rFVIIa for sPPH. The RCT, and OS-1 and OS-2, included a control group of women who did not receive rFVIIa (with propensity score-matching used in OS-1 and OS-2), whereas OS-3 and OS-4 provided descriptive data for rFVIIa-exposed women only. Results: A total of 446 women exposed to rFVIIa and 1717 non-exposed controls were included. In the RCT, fewer rFVIIa-exposed women (50% [21/42]) had an invasive procedure versus non-exposed women (91% [38/42]; odds ratio: 0.11; 95% confidence interval: 0.03-0.35). In OS-1, more rFVIIa-exposed women (58% [22/38]) had an invasive procedure versus non-exposed women (35% [13.3/38]; odds ratio: 2.46; 95% confidence interval: 1.06-5.99). In OS-2, 17% (3/18) of rFVIIa-exposed women and 32% (5.6/17.8) of non-exposed women had an invasive procedure (odds ratio: 0.33; 95% confidence interval: 0.03-1.75). Across all included women, TEs occurred in 1.5% (0.2% arterial and 1.2% venous) of rFVIIa-exposed women and 1.6% (0.2% arterial and 1.4% venous) of non-exposed women with available data. Conclusions: The positive treatment effect of rFVIIa on the RCT was not confirmed in the OS. However, the safety analysis did not show any increased incidence of TEs with rFVIIa treatment.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a McKinnon Edwards, Hellen $u Department of Obstetrics and Gynaecology, Copenhagen University Hospital Herlev, 2730 Herlev, Denmark $1 https://orcid.org/0000000198409944
700    1_
$a Zdanowicz, Jarmila A $u Department of Obstetrics and Gynecology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland $1 https://orcid.org/0000000253617309
700    1_
$a van den Akker, Thomas $u Leiden University Medical Center, 2333 Leiden, The Netherlands $u Athena Institute, Vrije Universiteit, 1081 Amsterdam, The Netherlands
700    1_
$a Birkegård, Camilla $u Novo Nordisk A/S, 2860 Søborg, Denmark
700    1_
$a Blatný, Jan $u Department of Paediatric Oncology, University Hospital Brno, and Masaryk University, 625 00 Brno, Czech Republic
700    1_
$a van der Bom, Johanna G $u Leiden University Medical Center, 2333 Leiden, The Netherlands $1 https://orcid.org/0000000190952475
700    1_
$a Colucci, Giuseppe $u Department of Obstetrics and Gynecology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland $u Clinica Sant'Anna, 6924 Sorengo, Switzerland $u University of Basel, 4001 Basel, Switzerland $1 https://orcid.org/0000000223798751
700    1_
$a van Duuren, Derek $u Leiden University Medical Center, 2333 Leiden, The Netherlands
700    1_
$a van Geloven, Nan $u Leiden University Medical Center, 2333 Leiden, The Netherlands
700    1_
$a Henriquez, Dacia D C A $u Leiden University Medical Center, 2333 Leiden, The Netherlands $u Amsterdam University Medical Center, University of Amsterdam, 1105 Amsterdam, The Netherlands
700    1_
$a Knight, Marian $u National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK $1 https://orcid.org/0000000219844575
700    1_
$a Korsholm, Lars $u Novo Nordisk A/S, 2860 Søborg, Denmark
700    1_
$a Landorph, Andrea $u Novo Nordisk A/S, 2860 Søborg, Denmark
700    1_
$a Lavigne Lissalde, Géraldine $u Department of Hematology, University Hospital, 30900 Nîmes, France
700    1_
$a McQuilten, Zoe K $u Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia $u Department of Haematology, Monash Health, Melbourne 3004, Australia
700    1_
$a Surbek, Daniel $u Department of Obstetrics and Gynecology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland $1 https://orcid.org/0000000177051584
700    1_
$a Wellard, Cameron $u Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia $1 https://orcid.org/0000000261155394
700    1_
$a Wood, Erica M $u Transfusion Research Unit, Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia $u Department of Haematology, Monash Health, Melbourne 3004, Australia
700    1_
$a Mercier, Frederic J $u Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Université Paris Saclay, 92140 Clamart, France $1 https://orcid.org/0000000212892849
773    0_
$w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 13, č. 9 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38731185 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240723 $b ABA008
991    __
$a 20240726151426 $b ABA008
999    __
$a ok $b bmc $g 2125504 $s 1224735
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 13 $c 9 $e 20240501 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
GRA    __
$a Sponsor $p Novo Nordisk (Denmark)
LZP    __
$a Pubmed-20240723
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace